Shares of Jazz Pharmaceuticals (JAZZ) rose sharply during the first hour of trade Monday, but settled into a range for the remainder of the day. The stock closed up by 7.17 at $55.29, with volume at a 4 1/2 month high.
Jazz Pharmaceuticals surged past resistance Monday and set a new high for the year. The company reportedly received a positive ruling from its Xyrem patent lawsuit against Roxane Laboratories.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.